Vera Therapeutics, Inc. $VERA Holdings Lifted by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 87.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,317 shares of the company’s stock after acquiring an additional 25,750 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Vera Therapeutics were worth $1,608,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in VERA. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics in the 2nd quarter worth approximately $51,000. Virtus Investment Advisers LLC grew its position in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares in the last quarter. Fifth Third Bancorp acquired a new stake in shares of Vera Therapeutics during the 2nd quarter valued at $102,000. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Vera Therapeutics by 13.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after acquiring an additional 615 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VERA. The Goldman Sachs Group boosted their target price on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Wedbush lifted their price target on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Bank of America boosted their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Finally, JPMorgan Chase & Co. cut their price target on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $74.83.

Vera Therapeutics Stock Performance

VERA stock opened at $45.11 on Thursday. The firm has a 50 day simple moving average of $45.25 and a 200 day simple moving average of $32.32. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $56.05. The stock has a market cap of $2.88 billion, a P/E ratio of -11.31 and a beta of 1.16. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the business posted ($0.85) EPS. Research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the completion of the sale, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Patrick G. Enright acquired 5,882 shares of Vera Therapeutics stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the transaction, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 16.30% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.